Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
DOI
 |
|
Open Access Green as soon as Postprint is submitted to ZB.
Evaluation of IDH1G105 polymorphism as prognostic marker in intermediate-risk AML.
Ann. Hematol. 94, 1991-2001 (2015)
Germline polymorphisms in genes mutated in acute myeloid leukemia (AML) may have prognostic impact. Therefore, the relevance of the polymorphism IDH1G105 (IDH1105GGT minor allele) was evaluated in the context of concomitant molecular mutations in a cohort of 507 AML cases with intermediate-risk cytogenetics. In addition, a cohort of 475 healthy controls was analyzed for this polymorphism. IDH1105GGT minor allele was found in 10 % of AML patients and 9 % of healthy controls. While no differences were seen with regard to cytomorphology or cytogenetics, immunophenotyping revealed significantly reduced expression of the progenitor marker CD34 in AML cases harboring IDH1105GGT minor allele. Cases with IDH1105GGT minor allele as compared to those with the IDH1105GGC major allele had significantly longer event-free survival (EFS) (median 16 vs 11 months, p = 0.013) which was most pronounced in the age group >60 years (median 14 vs 9 months, p = 0.007) and in the NPM1 mutated/FLT3-ITD/FLT3wt ratio <0.5 group (median 61 vs 13 months, p = 0.012). However, this association is not independent of other prognostic parameters, and we conclude that IDH1105GGT minor allele has to be considered in the context of the genetic background of the individual AML analyzed.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Aml ; Idh1 ; Idh2 ; Polymorphism ; Prognosis
ISSN (print) / ISBN
0939-5555
e-ISSN
1432-0584
Journal
Annals of Hematology
Quellenangaben
Volume: 94,
Issue: 12,
Pages: 1991-2001
Publisher
Springer
Non-patent literature
Publications
Reviewing status
Peer reviewed